15.1 C
Delhi
Friday, January 16, 2026

Tag: Novo Nordisk

Eli Lilly Hits $1 Trillion Valuation on Weight-Loss Drug Demand

Eli Lilly becomes first pharma firm to reach $1 trillion market cap as weight-loss drugs drive 47% stock surge and 54% revenue growth.

Novo Nordisk Cuts Wegovy Price, Plans Oral Weight-Loss Pill Launch

Novo Nordisk reduces Wegovy price to $349 monthly and prepares oral version to compete with Eli Lilly in the US weight-loss drug market.

Novo Nordisk Partners With Emcure Pharma to Launch Weight Loss Drug Poviztra

Novo Nordisk collaborates with Emcure Pharma to expand access to Poviztra weight loss injection across India, strengthening obesity treatment availability.

Pfizer Wins £7.7bn Bidding War for Weight-Loss Drug Firm

US pharma giant Pfizer triumphs over Novo Nordisk in dramatic takeover battle for Metsera, securing position in booming weight-loss drug market.

Pfizer Wins $10 Billion Metsera Acquisition After Beating Novo Nordisk

Pfizer secures obesity treatment specialist Metsera in $10 billion deal after intense bidding war. Board approves improved offer amid FTC regulatory concerns.

Pfizer Acquires Metsera in $10 Billion Weight-Loss Drug Deal

Pfizer wins competitive bidding against Novo Nordisk to acquire weight-loss startup Metsera in a landmark $10 billion pharmaceutical acquisition.

Novo Nordisk Cuts Forecasts Again Amid Weight-Loss Drug Competition

Ozempic maker Novo Nordisk slashes financial guidance for the fourth time as competition from Eli Lilly and copycat drugs intensifies in the weight-loss market.

Novo Nordisk Q3 Profit Falls 27%, Cuts 9,000 Jobs Amid Restructuring

Ozempic maker Novo Nordisk reports declining profits, job cuts and lowered outlook amid increasing competition in obesity drug market.